<DOC>
	<DOCNO>NCT01612377</DOCNO>
	<brief_summary>This study compare experimental drug call Z102 ( combination prednisolone dipyridamole , prednisone 5mg prednisone 7.5mg patient moderate severe Rheumatoid Arthritis period 52 week .</brief_summary>
	<brief_title>Long Term Safety Trial z102 Prednisone Patients With Moderate Severe Rheumatoid Arthritis</brief_title>
	<detailed_description>This long-term Phase II safety study approximately 52 week duration . Eligible patient complete least 6 week Protocol Z102-008 meet inclusion exclusion criterion study . All patient up-titrated Z102 3 week receive prednisone 5.0 mg 7.5 mg : Primary objective : - Adverse event ( AEs ) - Vital sign - Clinical laboratory clinical chemistry evaluation Secondary objective : - Joint image bone density - DAS28-CRP individual component - Patient Global Assessment Disease Activity - American College Rheumatology criterion ( ACR 20 , ACR 50 , ACR 70 ) - Multidimensional Assessment Fatigue ( MAF ) - Time failure</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Dipyridamole</mesh_term>
	<criteria>Have complete 12 week Protocol Z102008 discontinue participate least 6 week randomize withdrawal portion Z102008 acceptable reason Have meet inclusion/exclusion criterion enrollment Protocol Z102008 Have DMARD therapy least 90 day stable DMARD dose without dosage adjustment modification 6 week prior enrollment Protocol Z102008 , able maintain dose conventional DMARD therapy Protocol Z102009 participation Did complete 6 week doubleblind section Protocol Z102008 , discontinue Protocol Z102008 reason AE , protocol violation , noncompliance Active cardiovascular disease , unless well control appropriate treatment , minimum 3 month prior screen enrollment Protocol Z102008 Currently take aspirin reason cardiovascular prophylaxis total daily dose great 325 mg Taking oral steroid daily prednisone dose , equivalent , &gt; 10 mg/day within past 2 week Intraarticular , intramuscular , intravenous glucocorticoid must give least 6 week prior enter study Protocol Z102008 Protocol Z102009 , time study , anticipate give time study The need continue use one multiple NSAIDs time , use acetaminophen chronic basis All opiate use prohibit . Use medication herbs nonpharmacological treatment ( e.g. , acupuncture ) use treatment pain prohibit Has , , active severe infection recent invasive surgical procedure within 30 day Protocol Z102008 Protocol Z102009 initiation HIV , hepatitis B , hepatitis C infection Has undergone administration investigational drug within 30 day study All biologic agent exclude 90 day prior Screening conduct Protocol Z102008 , Protocol Z102009 Has undergone administration rituximab Bcell deplete investigational drug within 6 month Protocol Z102008 Screening Protocol Z102009 initiation , time participation study Protocol Z102008 Has history hypersensitivity reaction glucocorticoid and/or dipyridamole Known suspected history alcohol drug abuse within 2 year prior Screening Protocol Z102008 Has medical condition may interfere conduct study opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Moderate Severe</keyword>
</DOC>